Abstract: The present invention relates to a cell to be stably cultured in a medium, which cell is adjusted for the production of oligosaccharides, the cell being transformed to comprise at least one nucleic acid sequence coding for an enzyme involved in oligosaccharide synthesis. In addition the cell is transformed to comprise at least one nucleic acid sequence coding for a protein of the sugar efflux transporter family, a functional homolog or derivative thereof. Further, the invention concerns a method for the production of oligosaccharides involving above cell.
Type:
Application
Filed:
December 9, 2013
Publication date:
May 1, 2014
Applicant:
JENNEWEIN BIOTECHNOLOGIE GmbH
Inventors:
Stefan Jennewein, Eric Huefner, Julia Parkot
Abstract: Provided are hydrolases, including lipases, saturases, palmitases and/or stearatases, and polynucleotides encoding them, and methods of making and using these polynucleotides and polypeptides. Further provided are polypeptides, e.g., enzymes, having a hydrolase activity, e.g., lipases, saturases, palmitases and/or stearatases and methods for preparing low saturate or low trans fat oils, such as low saturate or low trans fat animal or vegetable oils, e.g., soy or canola oils.
Type:
Grant
Filed:
August 28, 2009
Date of Patent:
April 29, 2014
Assignee:
DSM IP Assets B.V.
Inventors:
Nelson R. Barton, Analia Bueno, Joslin G. Cuenca, Tim S. Hitchman, Katie A. Kline, Jonathan D. Lyon, Mark L. Miller, Mark A. Wall, Christopher L. G. Dayton
Abstract: The present invention relates to isolated polypeptides having organophosphorous hydrolase activity and isolated polynucleotides encoding the polypeptides. The invention also relates to nucleic acid constructs, vectors, and host cells comprising the polynucleotides as well as methods of producing and using the polypeptides.
Abstract: The invention features methods for producing isoprene from cultured cells. The invention also provides compositions that include these cultured cells.
Type:
Grant
Filed:
August 30, 2012
Date of Patent:
April 29, 2014
Assignees:
Danisco US Inc., The Goodyear Tire & Rubber Company
Inventors:
Marguerite A. Cervin, Gopal K. Chotani, Frank J. Feher, Richard La Duca, Joseph C. McAuliffe, Andrei Miasnikov, Caroline M. Peres, Aaron S. Puhala, Karl J. Sanford, Fernando Valle, Gregory M. Whited
Abstract: The present invention relates to a transcription factor found in filamentous fungi, especially in Aspergillii, DNA sequences coding for said factor, its transformation into and expression in fungal host organisms, and the use of said factor in such hosts for increasing the expression of a polypeptide of interest being produced by said host.
Abstract: The present invention relates to isolated polypeptides having cellulolytic enhancing activity and isolated polynucleotides encoding the polypeptides. The invention also relates to nucleic acid constructs, vectors, and host cells comprising the polynucleotides as well as methods of producing and using the polypeptides.
Type:
Application
Filed:
October 11, 2013
Publication date:
April 24, 2014
Inventors:
Suchindra Maiyuran, Randall Kramer, Paul Harris
Abstract: An acetyl xylan esterase variant having perhydrolytic activity is provided for producing peroxycarboxylic acids from carboxylic acid esters and a source of peroxygen. More specifically, a Thermotoga maritima acetyl xylan esterase gene was modified using error-prone PCR and site-directed mutagenesis to create an enzyme catalyst characterized by an increase in specific activity. The variant acetyl xylan esterase may be used to produce peroxycarboxylic acids suitable for use in a variety of applications such as cleaning, disinfecting, sanitizing, bleaching, wood pulp processing, and paper pulp processing applications.
Type:
Application
Filed:
October 22, 2012
Publication date:
April 24, 2014
Applicant:
E. I. DU PONT DE NEMOURS AND COMPANY
Inventors:
ROBERT DICOSIMO, MARK SCOTT PAYNE, JOHN EDWARD GAVAGAN
Abstract: This invention provides novel variant cellulolytic enzymes having improved activity and/or stability. In certain embodiments the variant cellulotyic enzymes comprise a glycoside hydrolase with or comprising a substitution at one or more positions corresponding to one or more of residues F64, A226, and/or E246 in Thermobifida fusca Cel9A enzyme. In certain embodiments the glycoside hydrolase is a variant of a family 9 glycoside hydrolase. In certain embodiments the glycoside hydrolase is a variant of a theme B family 9 glycoside hydrolase.
Type:
Application
Filed:
April 11, 2012
Publication date:
April 24, 2014
Applicant:
Novozymes A/S
Inventors:
Robert Blazej, Nicholas Toriello, Charles Emrich, Richard N. Cohen, Nitzan Koppel
Abstract: The present invention relates to isolated polypeptides having xylanase activity and polynucleotides encoding the polypeptides. The invention also relates to nucleic acid constructs, vectors, and host cells comprising the polynucleotides as well as methods of producing and using the polypeptides.
Abstract: The present invention relates to isolated polypeptides having cellulolytic enhancing activity and isolated polynucleotides encoding the polypeptides. The invention also relates to nucleic acid constructs, vectors, and host cells comprising the polynucleotides as well as methods of producing and using the polypeptides.
Type:
Application
Filed:
December 13, 2013
Publication date:
April 24, 2014
Applicants:
Novozymes, Inc., Novozymes A/S
Inventors:
Lan Tang, Ye Liu, Junxin Duan, Yu Zhang, Christian Isak Jorgensen, Randall Kramer
Abstract: The present invention provides compositions and methods for the expression of recombinant ?-glucosidase variants, as well as their use in the production of fermentable sugars from cellulosic biomass.
Type:
Application
Filed:
December 19, 2013
Publication date:
April 24, 2014
Applicant:
Codexis, Inc.
Inventors:
Dipnath Baidyaroy, Louis Clark, Lisa M. Newman
Abstract: By replacing the antigen-binding domain, the present inventors discovered novel polypeptide complexes that retain BiTE's strong anti-tumor activity and excellent safety properties, as well as have long half-life in blood and can damage various different target cells.
Abstract: The present disclosure provides antibodies that bind to human interleukin-6 (IL6). The antibodies can modulate IL6 signaling and thus used in treatment or prevention of IL6 associated diseases or disorders, particularly inflammatory disorder, rheumatoid arthritis (RA), angiogenesis, and cancer.
Abstract: The present compositions and methods relate to a thermostable carbonic anhydrases, polynucleotides encoding the carbonic anhydrase, and methods of make and/or use thereof. Formulations containing the carbonic anhydrase are suitable for use in extracting carbon dioxide.
Type:
Application
Filed:
May 8, 2012
Publication date:
April 24, 2014
Applicant:
DANISCO US INC.
Inventors:
Jing Ge, Ling Hua, Ayrookaran J. Poulose
Abstract: The invention relates to methods for the screening, identification and/or application of microorganisms of use in imparting beneficial properties to plants. In one embodiment, the method involves subjecting one or more plants to a growth medium in the presence of a set of microorganisms, selecting one or more plant, acquiring one or more microorganisms associated with the selected plant(s) and repeating the process one or more times. The method further involves the step of subjecting the one or more microorganisms to a conditioning and/or directed evolution process.
Abstract: Provided is an isolated polypeptide having triterpene methyltransferase activity. Also provided is an isolated nucleic acid molecule that encodes the triterpene methyltransferase polypeptides; a vector comprising the nucleic acid molecules that encode the triterpene methyltransferase polypeptides; and a host cell(s) transfected with the aforementioned nucleic acid molecule or vector. In another aspect, a method of producing a methylated triterpene is provided. The method comprises providing a metabolizable carbon source to a host cell transfected with a nucleic acid molecule that encodes a triterpene methyltransferase under conditions sufficient for production of a methylated triterpene. The method optionally further comprises isolating the methylated triterpene produced by the host cell.
Type:
Grant
Filed:
June 22, 2009
Date of Patent:
April 22, 2014
Assignee:
University of Kentucky Research Foundation
Inventors:
Joseph Chappell, Shigeru Okada, Scott Kinison, Tom Niehaus
Abstract: The present invention provides compositions and methods for producing ethanol wherein the amount of CO2 by-product is reduced during the fermentation process. The invention includes the use of oxidized lignin during the fermentation process.
Abstract: This invention relates to microorganisms that convert a carbon source to acrylate or other desirable products using propionyl-CoA as an intermediate. The invention provides genetically engineered microorganisms that carry out the conversion, as well as methods for producing acrylate by culturing the microorganisms. Also provided are microorganisms and methods for converting propionyl-CoA and propionate to 3-hydroxypropionyl-CoA, 3-hydroxypropionate (3-HP) and poly-3-hydroxypropionate.
Type:
Application
Filed:
October 15, 2012
Publication date:
April 17, 2014
Applicant:
THE PROCTER & GAMBLE COMPANY
Inventors:
Jun Xu, Phillip Richard Green, Charles Winston Saunders, Juan Estaban Velasquez
Abstract: The present invention relates to a host cell deficient in an essential gene, comprising a vector, said vector comprising at least said essential gene and an autonomous replication sequence, wherein the host cell is a filamentous fungal cell. The invention also relates to a host cell deficient in an essential gene, comprising a vector, said vector comprising at least said essential gene and an autonomous replication sequence, wherein the host cell comprises a recombinant polynucleotide construct comprising a polynucleotide encoding a biological compound of interest or a compound involved in the synthesis of a biological compound of interest.
Abstract: The present invention relates to a method for constructing a host cell expressing a polypeptide of interest from at least two ORF's stably integrated onto the chromosome of the host cell comprising the steps of: a) providing the at least two ORF's encoding the same polypeptide, wherein the at least two DNA sequences of the ORF's differ in at least one position; b) integrating the at least two ORF's in the same orientation on the host cell chromosome.
Type:
Application
Filed:
September 23, 2013
Publication date:
April 17, 2014
Inventors:
Steen Troels Jorgensen, Poul Erik Pedersen
Abstract: The present invention demonstrated that the modification of the Fc region of an antigen-binding molecule into an Fc region that does not form in a neutral pH range a heterotetramer complex containing two molecules of FcRn and an active Fc? receptor improved the pharmacokinetics of the antigen-binding molecule and reduced the immune response to the antigen-binding molecule. The present invention also revealed methods for producing antigen-binding molecules having the properties described above, and successfully demonstrated that pharmaceutical compositions containing as an active ingredient such an antigen-binding molecule or an antigen-binding molecule produced by a production method of the present invention have excellent features over conventional antigen-binding molecules in that when administered, they exhibit improved pharmacokinetics and reduced in vivo immune response.
Abstract: The present invention relates to isolated polypeptides having xylanase activity and isolated polynucleotides encoding the polypeptides. The invention also relates to nucleic acid constructs, vectors, and host cells comprising the polynucleotides as well as methods of producing and using the polypeptides.
Abstract: The invention generally relates to antibodies that bind to human folate receptor 1 and diagnostic assays for folate receptor 1-based therapies. Methods of using the antibodies to monitor therapy are further provided.
Type:
Application
Filed:
August 30, 2013
Publication date:
April 10, 2014
Inventors:
NATHAN E. TESTA, CHRISTINA N. CARRIGAN, OLGA AB, DANIEL TAVARES, BENI B. WOLF
Abstract: The present invention relates to methods for producing a biological substance, comprising: (a) cultivating a fungal host cell in a medium conducive for the production of the biological substance, wherein the fungal host cell comprises a first nucleic acid sequence encoding the biological substance operably linked to a second nucleic acid sequence comprising a promoter variant selected from the group consisting of SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 8, SEQ ID NO: 9, SEQ ID NO: 10, SEQ ID NO: 11, and SEQ ID NO: 12; and a subsequence thereof; and hybrid and tandem promoters thereof; and (b) isolating the biological substance from the cultivation medium. The present invention also relates to the isolated promoter variants and to constructs, vectors, and fungal host cells comprising the promoter variants operably linked to nucleic acid sequences encoding biological substances.
Abstract: The present invention relates to antibodies that specifically bind to IL12R?1, the non-signal transducing chain of both the heterodimeric IL12 and IL23 receptors. The invention more specifically relates to specific antibodies that are IL12 and IL23 receptor antagonists capable of inhibiting IL12/IL18 induced IFN? production of blood cells and compositions and methods of use for said antibodies to treat pathological disorders that can be treated by inhibiting IFN? production, IL12 and/IL23 signaling, such as rheumatoid arthritis, psoriasis or inflammatory bowel diseases or other autoimmune and inflammatory disorders.
Type:
Application
Filed:
October 3, 2013
Publication date:
April 10, 2014
Applicant:
NOVARTIS AG
Inventors:
Jose M. CARBALLIDO HERRERA, Stefan HARTLE, Christoph HEUSSER, Ingo KLAGGE, Andrea POLZER, Christoph SCHWAERZLER, Gabriela WOCHNIK-VELTRUP
Abstract: Proteins that bind IL-1? and IL-1? are described along with their use in compositions and methods for treating, preventing, and diagnosing IL-1-related disorders and for detecting IL-1? and IL-1? in cells, tissues, samples, and compositions.
Type:
Application
Filed:
December 12, 2013
Publication date:
April 10, 2014
Applicant:
ABBVIE, INC.
Inventors:
Chengbin WU, Dominic J. AMBROSI, Chung-ming HSIEH, Tariq GHAYUR
Abstract: Genetically encoded calcium indicator (GECI) polypeptides and the nucleic acid molecules encoding such polypeptides are provided. In addition, methods of using such nucleic acids and polypeptides in methods of screening for agonists or antagonists of G-protein coupled receptor (GPCR) or ion channels and methods of monitoring neural activity also are provided.
Type:
Application
Filed:
March 13, 2013
Publication date:
April 10, 2014
Applicant:
HOWARD HUGHES MEDICAL INSTITUTE
Inventors:
Loren Looger, Karel Svoboda, Douglas Kim, Rex Kerr
Abstract: The present invention relates to isolated polypeptides having beta-glucosidase activity, beta-xylosidase activity, or beta-glucosidase and beta-xylosidase activity and isolated polynucleotides encoding the polypeptides. The invention also relates to nucleic acid constructs, vectors, and host cells comprising the polynucleotides as well as methods of producing and using the polypeptides.
Abstract: Chimeric molecules comprising receptor activator of NF-?B ligand (RANKL) antibodies and parathyroid hormone/parathyroid hormone-related protein (PTH/PTHrP) peptides are described. Compositions and methods for the treatment of bone diseases are also described.
Type:
Application
Filed:
March 15, 2013
Publication date:
April 10, 2014
Applicant:
AMGEN INC.
Inventors:
Paul KOSTENUIK, Wenyan SHEN, Thomas C. BOONE
Abstract: Described are compositions and methods relating to variant filamentous fungi having altered growth characteristics. Such variants are well-suited for growth in submerged cultures, e.g., for the large-scale production of enzymes and other proteins for commercial applications.
Type:
Application
Filed:
April 20, 2012
Publication date:
April 10, 2014
Applicant:
DANISCO US INC.
Inventors:
Elizabeth A. Bodie, Robert James Pratt, II
Abstract: Described herein are compositions and methods for generating oxidoreductases for enantioselective reactions. Described herein are compositions and methods for generating neomorphic (R)-2-hydroxyacid dehydrogenases capable of enzymatically converting a 1-carboxy-2-ketoacid to a 1-carboxy-(R)-2-hydroxyacid, or the reverse reaction. Illustrative examples include (a) (R)-2-hydroxyadipate dehydrogenase and uses thereof for converting 2-oxoadipate to (R)-2-hydroxyadipate, or the reverse reaction; and (b) (R)-2-hydroxyglutarate dehydrogenase and uses thereof for converting 2-oxoglutarate to (R)-2-hydroxyglutarate, or the reverse reaction. Also described herein are compositions and methods for generating non-natural microbial organisms to enzymatically convert 2-oxoadipate to (E)-2-hexenedioate or adipate, or to enzymatically convert 2-oxoglutarate to (E)-2-pentenedioate or glutarate, or the respective reverse reactions.
Type:
Grant
Filed:
February 27, 2013
Date of Patent:
April 8, 2014
Assignee:
Duke University
Inventors:
Zachary James Reitman, Hai Yan, Bryan Daehahn Choi, John Howard Sampson
Abstract: From a bacterial strain isolated from an environmental sample, after enrichment in medium containing 1-butanol as the carbon source, a new enzyme with butanol dehydrogenase activity was identified. The enzyme can convert butyraldehyde to 1-butanol, isobutyraldehyde to isobutanol, as well as 2-butanone to 2-butanol and thus is useful for biosynthesis of butanol in recombinant microbial hosts producing these substrates. The encoding gene, named sadB, was isolated from the strain identified as an isolate of Achromobacter xylosoxidans.
Type:
Grant
Filed:
May 24, 2012
Date of Patent:
April 8, 2014
Assignee:
Butamax Advanced Biofuels LLC
Inventors:
Michael G. Bramucci, Andrew C. Eliot, Lori Ann Maggio-Hall, Charles E. Nakamura
Abstract: The present invention provides members that produce on a large scale a coenzyme-linked glucose dehydrogenase which has excellent substrate-recognizing ability toward glucose while providing low action on maltose. The present invention relates to a polynucleotide encoding a soluble coenzyme-linked glucose dehydrogenase that catalyzes the oxidation of glucose in the presence of an electron acceptor and has an activity toward maltose of 5% or lower; a polypeptide encoded by the nucleotide sequence of the polynucleotide; a recombinant vector carrying the polynucleotide; a transformed cell produced using the recombinant vector; a method for producing a polypeptide comprising culturing the transformed cell and collecting from the cultivated products a polypeptide that links to FAD to exert the glucose dehydration activity; a method for determination of glucose using the polypeptide; a reagent composition for determination of glucose; and a biosensor.
Abstract: The invention provides a Pseudomonas exotoxin A (PE) comprising an amino acid sequence having a substitution of one or more B-cell and/or T-cell epitopes. The invention further provides related chimeric molecules, as well as related nucleic acids, recombinant expression vectors, host cells, populations of cells, and pharmaceutical compositions. Methods of treating or preventing cancer in a mammal, methods of inhibiting the growth of a target cell, methods of producing the PE, and methods of producing the chimeric molecule are further provided by the invention.
Type:
Application
Filed:
June 7, 2012
Publication date:
April 3, 2014
Applicant:
The United States of America,as represented by the Secretary, Department of Health and Human Servic
Inventors:
Ira H. Pastan, Ronit Mazor, Masanori Onda, Aaron Vassall, Richard Beers, Jaime Eberle, Wenhai Liu
Abstract: The present invention relates to isolated polypeptides having endoglucanase activity and polynucleotides encoding the polypeptides. The invention also relates to nucleic acid constructs, vectors, and host cells comprising the polynucleotides as well as methods of producing and using the polypeptides.
Abstract: The invention relates to conjugates comprising a targeting moiety specific for the CXCR4 based on the polyphemusin-derived peptide and a therapeutic or imaging agent. The invention relates as well to the application of said conjugates for the therapy and diagnostics which require the specific targeting to CXCR4+ cells.
Abstract: Improved DLL4 binding proteins are described, including antibodies, CDR-grafted antibodies, human antibodies, and DLL4 binding fragments thereof, proteins that bind DLL4 with high affinity, and DLL4 binding proteins that neutralize DLL4 activity. The DLL4 binding proteins are useful for treating or preventing cancers and tumors and especially for treating or preventing tumor angiogenesis, and/or other angiogenesis-dependent diseases such as ocular neovascularization, or angiogenesis-independent diseases characterized by aberrant DLL4 expression or activity such as autoimmune disorders including multiple sclerosis.
Type:
Application
Filed:
November 26, 2013
Publication date:
April 3, 2014
Applicant:
ABBVIE INC.
Inventors:
Lorenzo Benatuil, Erwin R. Boghaert, Jijie Gu, Maria Harris, Jonathan A. Hickson, Chung-Ming Hsieh, Yuliya Kutskova, Yingchun Li, Zhihong Liu, Susan Morgan-Lappe
Abstract: Disclosed herein are isolated immunogens including variant gp120 polypeptides. In an example, a variant gp120 polypeptide includes a deletion of at least 8 consecutive residues of the fourth conserved loop (C4) between residues 419 and 434 of gp120 according to HXB2 numbering. Also provided are isolated nucleic acid molecules encoding the disclosed isolated immunogens. In an example, an isolated nucleic acid molecule further includes a nucleic acid molecule encoding a hepatitis B surface antigen or a variant thereof. Compositions including the isolated immunogens including variant gp120 polypeptides are also disclosed. In some examples, a composition further includes a carrier protein, such as a hepatitis B surface antigen or a variant thereof (natural or recombinant). Viral-like particles are also provided including any of the disclosed isolated immunogens or compositions.
Type:
Application
Filed:
November 25, 2013
Publication date:
April 3, 2014
Applicant:
The United States of America, as Represented by the Secretary, Dept. of Health & Human Service
Abstract: Described are compositions and methods relating to variant filamentous fungi having altered growth characteristics. Such variants are well-suited for growth in submerged cultures, e.g., for the large-scale production of enzymes and other proteins for commercial applications.
Type:
Application
Filed:
April 20, 2012
Publication date:
April 3, 2014
Applicant:
DANISCO US INC.
Inventors:
Elizabeth A. Bodie, Robert James Pratt, II
Abstract: The present invention relates to isolated polypeptides having cellulolytic enhancing activity and isolated polynucleotides encoding the polypeptides. The invention also relates to nucleic acid constructs, vectors, and host cells comprising the polynucleotides as well as methods for producing and using the polypeptides.
Type:
Application
Filed:
October 12, 2012
Publication date:
April 3, 2014
Applicant:
Novozymes, Inc.
Inventors:
Kimberly Brown, Paul Harris, Elizabeth Zaretsky, Edward Re, Elena Vlasenko, Keith McFarland, Alfredo Lopez de Leon
Abstract: The present invention relates to isolated polypeptides having endoglucanase activity and isolated polynucleotides encoding the polypeptides. The invention also relates to nucleic acid constructs, vectors, and host cells comprising the polynucleotides as well as methods of producing and using the polypeptides.
Abstract: The present invention relates to a process for producing a human-type glycoprotein having reduced glycosylation by genetically manipulating an enzyme involved in glycosylation using a Hansenula polymorpha system. In detail, the present invention relates to a process for producing a human-type glycoprotein by identifying a dolichyl-phosphate-mannose dependent ?-1,3-mannosyltransferase gene from H. polymorpha, constructing a H. polymorpha mutant strain producing a glycoprotein exhibiting reduced glycosylation by disrupting the identified gene, and subjecting the mutant strain to various genetic manipulations for the synthesis of human-type glycan.
Type:
Grant
Filed:
April 19, 2012
Date of Patent:
April 1, 2014
Assignee:
Korea Research Institute of Bioscience and Biotechnology
Inventors:
Hyun Ah Kang, Jeong Seok Park, Moo Woong Kim, Eun Jung Kim, Hye Yun Moon, Doo Byoung Oh, Joo Hyung Heo, Sang Ki Rhee
Abstract: The present invention relates to peptides, nucleic acids, and cells for use in the immunotherapy of cancer. The present invention furthermore relates to survivin-derived tumor-associated cytotoxic T cell (CTL) peptide epitopes, alone or in combination with other tumor-associated peptides that serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses. The present invention specifically relates to three novel peptide sequences and variants thereof derived from HLA class I and class II molecules of human tumor cells that can be used in vaccine compositions for eliciting anti-tumor immune responses.
Type:
Application
Filed:
March 15, 2013
Publication date:
March 27, 2014
Applicant:
IMMATICS BIOTECHNOLOGIES GMBH
Inventors:
Toni WEINSCHENK, Peter LEWANDROWSKI, Oliver SCHOOR
Abstract: A method of gene editing or gene stacking within a FAD2 loci by cleaving, in a site directed manner, a location in a FAD2 gene in a cell, to generate a break in the FAD2 gene and then ligating into the break a nucleic acid molecule associated with one or more traits of interest is disclosed.
Type:
Application
Filed:
September 5, 2013
Publication date:
March 27, 2014
Inventors:
Noel Cogan, John Forster, Matthew Hayden, Tim Sawbridge, German Spangenberg, Steven R. Webb, Manju Gupta, William Michael Ainley, Matthew J. Henry, Jeffrey C. Miller, Dmitry Y. Guschin
Abstract: This application provides transcription activator-like effector nucleases (TALENs), polynucleotide sequences encoding the TALENs, expression cassettes for producing TALENs to target cleavage of nucleic acids, and methods of producing and using the TALENs.
Abstract: The present invention relates to glucoamylase variants. In particular, the invention relates to variants in the starch binding domain (SBD) of a glucoamylase. The invention also relates to variants having altered properties (e.g., improved thermostability and/or increased specific activity) as compared to a corresponding parent glucoamylase. The present invention also provides enzyme compositions comprising the variant glucoamylases; DNA constructs comprising polynucleotides encoding the variants; and methods of producing the glucoamylase variants in host cells.
Type:
Application
Filed:
August 30, 2013
Publication date:
March 27, 2014
Applicant:
Danisco US Inc.
Inventors:
Wolfgang Aehle, Richard R. Bott, Igor Nikoaev, Martijn Scheffers, Piet Van Solingen, Casper Vroemen
Abstract: Disclosed herein are compounds that inhibit Hsp90 interactions with IAP proteins, such as Survivin, XIAP, cIAP1, or cIAP2, and methods for identifying and using such compounds.